These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15503293)

  • 1. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy.
    Broxson EH; Dole M; Wong R; Laya BF; Stork L
    Pediatr Blood Cancer; 2005 Mar; 44(3):226-31. PubMed ID: 15503293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
    Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
    Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience.
    Ravikumara M; Hill FG; Wilson DC; Gillett PM; Thomas A; Brown R; Darbyshire PJ; McKiernan PJ
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):535-8. PubMed ID: 16707977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
    Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
    Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A; Teml A; Reinisch W; Ulbrich G; Wrba F; Homoncik M; Gangl A; Peck-Radosavljevic M; Vogelsang H
    Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.
    Lancaster DL; Patel N; Lennard L; Lilleyman JS
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term risk of portal hypertension and related complications in children treated with 6-thioguanine for acute lymphoblastic leukemia: A single-center experience.
    Roy Moulik N; M Taj M
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28233441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of children with 6-thioguanine-related chronic hepatoxicity following treatment for acute lymphoblastic leukaemia.
    Rawat D; Gillett PM; Devadason D; Wilson DC; McKiernan PJ
    J Pediatr Gastroenterol Nutr; 2011 Nov; 53(5):478-9. PubMed ID: 21701407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
    Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
    Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory predictors of esophageal varices in children and adolescents with portal hypertension syndrome.
    Fagundes ED; Ferreira AR; Roquete ML; Penna FJ; Goulart EM; Figueiredo Filho PP; Bittencourt PF; Carvalho SD; Albuquerque W
    J Pediatr Gastroenterol Nutr; 2008 Feb; 46(2):178-83. PubMed ID: 18223377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
    Kitchen BJ; Balis FM; Poplack DG; O'Brien M; Craig CE; Adamson PC
    Clin Cancer Res; 1997 May; 3(5):713-7. PubMed ID: 9815740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy.
    Warren DJ; Andersen A; Slørdal L
    Cancer Res; 1995 Apr; 55(8):1670-4. PubMed ID: 7712473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.
    De Bruyne R; Portmann B; Samyn M; Bansal S; Knisely A; Mieli-Vergani G; Dhawan A
    J Hepatol; 2006 Feb; 44(2):407-10. PubMed ID: 16226335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
    Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
    Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
    Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
    Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
    Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.